Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011

References

• Gilleece Y, Chadwick DR, Breuer J, et al. For the BHIVA Guidelines Subcommittee. British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010. HIV Med 2010;11:611-9
   PubMed Web of Science ®Google Scholar
• Gazzard BG; on behalf of the BHIVA Treatment Guideline Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008;9:563-608
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372:646-55
   PubMed Web of Science ®Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19:685-94
   PubMed Web of Science ®Google Scholar
• Anderson KM, Wilson PWF, Odell PM, et al. An updated coronary risk profile. A statement for health professions. Circulation 1991;83:356-62
   PubMed Web of Science ®Google Scholar
• Simpson KN, Luo MP, Chumney EG, et al. Cost effectiveness of using lopinavir/ritonavir vs. nelfinavir as the first highly active antiretroviral regimen for HIV infection. HIV Clin Trials 2004;5:294-304
   PubMed Web of Science ®Google Scholar
• Simpson KN, Luo M, Chumney ECG, et al. Cost-effectiveness of lopinavir/ritonavir compared to atazanavir in antiretroviral-naïve patients: modeling the combined effects of HIV and heart disease. Clin Drug Investig 2007;27:67-74
   PubMed Web of Science ®Google Scholar
• Simpson KN, Roberts G, Hicks CB, et al. Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States. HIV Clin Trials 2008;9:22-237
   Google Scholar
• Ghani AC, de Wolf F, Ferguson NM, et al. Surrogate markers for disease progression in treated HIV infection. J Acquir Immune Defic Syndr 2001;28:226-31
   PubMed Web of Science ®Google Scholar
• Ghani AC, Henley WE, Donnelly CA, et al. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases. AIDS 2001;15:1133-42
   PubMed Web of Science ®Google Scholar
• Mocroft A, Ruiz L, Reiss P, et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003;17:1741-51
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQoL health states. Med Care 1997;35:1095-108
   PubMed Web of Science ®Google Scholar
• Castiel D, Herve C, Gaillard M, et al. Cost-utility analysis of early thrombolytic therapy. PharmacoEconomics 1992;1:438-42
   PubMedGoogle Scholar
• Mrus JM, Yi MS, Freedberg KA, et al. Utilities derived from visual analog scale scores in patients with HIV/AIDS. Med Decis Making 2003;23:414-21
   PubMed Web of Science ®Google Scholar
• Beck EJ, Mandalia S, Lo G, et al; Gazzard B for the NPMS-HHC Steering Group. Use and cost of HIV ServiceProvision in UK NPMS -HHC Sites: aggregate analyses January 1996 to December 2006. NPMS-HHC Coordinating and Analytic Centre, St. Stephen’s Centre, Chelsea and Westminster Hospital Trust, London, UK, 2008
   Google Scholar
• Molina J-M, Andrade-Villanueva J, Echevarria J, et al.; CASTLE Study Team. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010;53:323-32
   PubMed Web of Science ®Google Scholar
• Friis-Moller. Exposure to PIs and NNRTI and risk of myocardial infarction: results of the D:A:D Study. Presented at the 13th Conference on Retroviruses and Opportunistic Infections (CROI). Denver, CO: 5–8 February 2006; Session 35, Oral Abstract 144
   Google Scholar
• Worm SW, Kamara DA, Reiss P, et al. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS 2011;25:1497-504
   PubMed Web of Science ®Google Scholar
• Broder MS, Chang EY, Bentley TGK, et al. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States. J Med Econ 2011;14:167-78
   PubMedGoogle Scholar
• Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Medical Care 2006;44:990-7
   PubMed Web of Science ®Google Scholar
• Simpson KN, Dietz B, Baran R, et al. Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data. Cost Eff Resour Alloc 2011;9:5
   PubMedGoogle Scholar
• Beck EJ, Mandalia S, Lo G, et al; NPMS-HHC Steering Group. Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006. PLoS One 2011;6:e20200
   PubMedGoogle Scholar
• Beck EJ, Mandalia S, Youle M, et al. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996--2002). Int J STD AIDS 2008;19:297-304
   PubMed Web of Science ®Google Scholar
• Simpson KN, Jones WJ, Rajagopalan R, et al. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain. Clin Drug Investig 2007;27:807-17
   PubMed Web of Science ®Google Scholar
• Moeremans K, Annemans L, Lothgren M, et al. Cost effectiveness of darunavir/ritonavir 600/100mg bid in protease Inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics 2010;28(1 Suppl):107-28
   PubMedGoogle Scholar
• Moeremans K, Hemmett L, Hjelmgren J, et al. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics 2010;28(1 Suppl):147-67
   PubMedGoogle Scholar
• Gazzard B, Hill A, Anceau A. Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices. Appl Health Econ Health Policy 2011;9:217-23
   PubMedGoogle Scholar